OBJECTIVES: To evaluate the effectiveness of high-dose erythromycin to treat feeding intolerance in preterm infants predominantly fed milk formula. DESIGN: This study is a prospective randomized controlled trial on 60 premature infants suffering from feeding intolerance. Thirty infants were given oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days or until they reached full enteral feeds. Randomization was stratified according to gestational age <32 weeks or ≥32 weeks gestation. The primary end point was the time taken to establish full enteral feeding since enrollment. Potential adverse effects associated with erythromycin were also monitored. Student's t test was used for comparison of continuous variables and χ(2)for categorical data. RESULTS: In infants <32 weeks, the use of erythromycin was associated with more daily weight gain (12.8 ± 2.6 g vs. 9.2 ± 5.3 g, p = 0.04) compared to the control group. Time to reach full feed did not differ between the erythromycin (13.8 ± 3.9 days) and the control (17.46 ± 4.9 days) groups (p = 0.07). In infants ≥32 weeks, there were no differences between the erythromycin and the control groups. CONCLUSION: High-dose erythromycin is associated with greater weight gain in preterm infants <32 weeks gestational age, who are predominantly fed cow's milk-based protein formulas.
RCT Entities:
OBJECTIVES: To evaluate the effectiveness of high-dose erythromycin to treat feeding intolerance in preterm infants predominantly fed milk formula. DESIGN: This study is a prospective randomized controlled trial on 60 premature infants suffering from feeding intolerance. Thirty infants were given oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days or until they reached full enteral feeds. Randomization was stratified according to gestational age <32 weeks or ≥32 weeks gestation. The primary end point was the time taken to establish full enteral feeding since enrollment. Potential adverse effects associated with erythromycin were also monitored. Student's t test was used for comparison of continuous variables and χ(2)for categorical data. RESULTS: In infants <32 weeks, the use of erythromycin was associated with more daily weight gain (12.8 ± 2.6 g vs. 9.2 ± 5.3 g, p = 0.04) compared to the control group. Time to reach full feed did not differ between the erythromycin (13.8 ± 3.9 days) and the control (17.46 ± 4.9 days) groups (p = 0.07). In infants ≥32 weeks, there were no differences between the erythromycin and the control groups. CONCLUSION: High-dose erythromycin is associated with greater weight gain in preterm infants <32 weeks gestational age, who are predominantly fed cow's milk-based protein formulas.
Authors: Elizabeth T Rogawski; Daniel J Westreich; Linda S Adair; Sylvia Becker-Dreps; Robert S Sandler; Rajiv Sarkar; Deepthi Kattula; Honorine D Ward; Steven Meshnick; Gagandeep Kang Journal: J Pediatr Date: 2015-09-12 Impact factor: 4.406
Authors: Jessica E Ericson; Christopher Arnold; Jomani Cheeseman; Jordan Cho; Sarah Kaneko; Ele'na Wilson; Reese H Clark; Daniel K Benjamin; Vivian Chu; P Brian Smith; Christoph P Hornik Journal: J Pediatr Gastroenterol Nutr Date: 2015-09 Impact factor: 3.288
Authors: Sourabh Dutta; Balpreet Singh; Lorraine Chessell; Jennifer Wilson; Marianne Janes; Kimberley McDonald; Shaneela Shahid; Victoria A Gardner; Aune Hjartarson; Margaret Purcha; Jennifer Watson; Chris de Boer; Barbara Gaal; Christoph Fusch Journal: Nutrients Date: 2015-01-08 Impact factor: 5.717
Authors: B S Schwartz; J Pollak; L Bailey-Davis; A G Hirsch; S E Cosgrove; C Nau; A M Kress; T A Glass; K Bandeen-Roche Journal: Int J Obes (Lond) Date: 2015-10-21 Impact factor: 5.095